Advaxis Overview

  • Founded
  • 1987

Founded
  • Status
  • Public

  • Employees
  • 15

Employees
  • Stock Symbol
  • ADXS

Stock Symbol
  • Investments
  • 2

  • Share Price
  • $3.38

  • (As of Friday Closing)

Advaxis General Information

Description

Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate-Specific Antigen (PSA) associated with prostate cancer.

Contact Information

Website
www.advaxis.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
PINX
Primary Office
  • 9 Deer Park Drive
  • Suite K-1
  • Monmouth Junction, NJ 08852
  • United States
+1 (609) 000-0000

Advaxis Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Advaxis Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.38 $3.39 $3.00 - $51.60 $6.15M 1.82M 5.32K -$6.90

Advaxis Financials Summary

In Thousands,
USD
TTM 30-Apr-2022 FY 2021 31-Oct-2021 FY 2020 31-Oct-2020 FY 2019 31-Oct-2019
EV (20,351) 25,319 4,769 (33,934)
Revenue 500 3,240 253 20,884
EBITDA (11,093) (16,787) (24,551) (15,514)
Net Income (11,583) (17,862) (26,469) (16,612)
Total Assets 37,518 46,780 38,526 45,257
Total Debt 27 40 6,017 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Advaxis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Advaxis‘s full profile, request access.

Request a free trial

Advaxis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, devel
Biotechnology
Monmouth Junction, NJ
15 As of 2021
00000
00000000

00000

voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non
0000 000000000
New York, NY
00 As of 0000
000.00
000000000000 000.00

000000

o eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
0000000000000
Smyrna, GA
00 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Advaxis Competitors (80)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ember Therapeutics Formerly VC-backed New York, NY 00 000.00 000000000000 000.00
000000 Corporation Smyrna, GA 00 000.00 000000000 000.00
00000 000000000000 Formerly VC-backed Waltham, MA 000 00000 00000000 00000
0000000 0000000000 Formerly VC-backed Watertown, MA 00 00000 000000000 00000
00000000 Formerly VC-backed Mainz, Germany 0000 00.000 00000000 00.000
You’re viewing 5 of 80 competitors. Get the full list »

Advaxis Patents

Advaxis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3785029-A1 Compositions and methods for evaluating potency of listeria-based immunotherapeutics Pending 27-Apr-2018 0000000000
US-20210239681-A1 Compositions and methods for evaluating potency of listeria-based immunotherapeutics Pending 27-Apr-2018 0000000000
AU-2019231783-A1 Compositions and methods for evaluating attenuation and infectivity of listeria strains Pending 09-Mar-2018 00000000000
US-20210003558-A1 Compositions and methods for evaluating attenuation and infectivity of listeria strains Pending 09-Mar-2018 00000000000
JP-2021516972-A Compositions and methods for assessing attenuation and infectivity of listeria strains Pending 09-Mar-2018 G01N33/5014
To view Advaxis’s complete patent history, request access »

Advaxis Executive Team (15)

Name Title Board Seat Contact Info
Molly Henderson Chief Financial Officer
Christopher Duke Chief Operating Officer & Senior Vice President
Sherrie Balog Executive Assistant
James Patton Ph.D Vice Chairman
You’re viewing 4 of 15 executive team members. Get the full list »

Advaxis Board Members (9)

Name Representing Role Since
00000 000000 00.0 Advaxis Vice Chairman 000 0000
000000 00000 00.0 Self Scientific Advisory Board 000 0000
0000 00000 Self Board Member 000 0000
00000 000000 00 Self Director 000 0000
000000 00000000 00.0 Self Chairman, Scientific Advisory Board & Scientific Founder 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Advaxis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Advaxis Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Advaxis‘s full profile, request access.

Request a free trial

Advaxis Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 06-Jul-2021 0000000 00 Drug Discovery 0000000 0
Great Expectations and Associates 12-Nov-2004 Merger/Acquisition Holding Companies
To view Advaxis’s complete acquisitions history, request access »